Thoracic endovascular repair as a safe management strategy for aortobronchial XXXX .

@entity1 @entity292
OBJECTIVES: This study assessed the safety and efficacy of thoracic endovascular aortic repair (TEVAR) in the management of aortobronchial @entity292 . METHODS: A retrospective review was performed at Emory University Hospital to identify all @entity1 who presented with an aortobronchial fistula. The diagnosis was based on clinical, radiologic, and bronchoscopic findings. @entity1 who underwent TEVAR as definitive management of these @entity292 were identified. Demographics, history of thoracic aorta pathology or intervention, type and number of endografts used, need for reoperation, and clinical and radiologic follow-up data were collected for each individual. RESULTS: Between 2000 and 2009, 11 @entity1 received TEVAR as definitive management of aortobronchial @entity292 . Technical success was achieved in 10 @entity1 (91%). Six @entity1 (55%) had previously undergone thoracic aortic surgery. A proximal type 1 endoleak developed in one @entity1 after graft deployment and required reintervention for additional graft placement. No intraoperative or 30-day deaths occurred. Postoperative clinical and radiographic assessment was a mean of 8.8 months (range, 1-40 months). For all 10 @entity1 in whom technical success was achieved at the initial operation, no endoleaks were noted at the follow-up CT scan. In addition, no @entity1 required a further intervention. CONCLUSIONS: This study represents the largest reported series on the use of TEVAR in the management of aortobronchial @entity292 . Supported by postoperative surveillance imaging and clinical evaluation, TEVAR has proven to be a safe and effective management strategy for an otherwise lethal condition. Long-term follow-up data are needed to ascertain the durability of this approach.
